Trifluridine
Desmoid Tumor
Parabilis Medicines, Inc.Small moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Desmoid Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nivolumab Parabilis Medicines, Inc. | Phase 2 | B |
Ipilimumab National Cancer Institute (NCI) | Phase 2 | CCC |
Nab-Rapamycin Sarcoma Oncology Research Center, LLC | Phase 1/2 | CCC |
Fog-001 Parabilis Medicines, Inc. | Phase 1/2 | CCC |
Tegavivint Children's Oncology Group | Phase 1/2 | CCC |
Tipiracil Parabilis Medicines, Inc. | Phase 1/2 | CCC |
N-Desmethyl-4-Hydroxytamoxifen National Cancer Institute (NCI) | Phase 1 | CC |
Fes F-18 Vanderbilt-Ingram Cancer Center | Early Phase 1 | C |
Same molecule, other indications
Trifluridine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →